sabizabulin
Showing 1 - 2 of 2
Metastatic Triple Negative Breast Cancer Trial (Sabizabulin, Sacituzumab Govitecan-hziy, Sabizabulin/Sacituzumab govitecan-hziy
Withdrawn
- Metastatic Triple Negative Breast Cancer
- Sabizabulin
- +2 more
- (no location specified)
Jan 24, 2022
Metastatic Breast Cancer Trial in United States (Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective
Not yet recruiting
- Metastatic Breast Cancer
- Sabizabulin
- Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator
-
Anchorage, Alaska
- +25 more
Dec 22, 2022